Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, m… Read more
Market Cap & Net Worth: Theralase Technologies Inc. (TLTFF)
Theralase Technologies Inc. (OTCQB:TLTFF) has a market capitalization of $37.09 Million ($37.09 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #23105 globally and #8113 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theralase Technologies Inc.'s stock price $0.14 by its total outstanding shares 264909216 (264.91 Million).
Theralase Technologies Inc. Market Cap History: 2015 to 2025
Theralase Technologies Inc.'s market capitalization history from 2015 to 2025. Data shows change from $82.12 Million to $37.09 Million (-4.89% CAGR).
Theralase Technologies Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theralase Technologies Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
43.58x
Theralase Technologies Inc.'s market cap is 43.58 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $82.12 Million | $1.95 Million | -$5.21 Million | 42.22x | N/A |
| 2016 | $50.33 Million | $1.92 Million | -$4.92 Million | 26.23x | N/A |
| 2017 | $51.34 Million | $2.34 Million | -$6.09 Million | 21.92x | N/A |
| 2018 | $60.24 Million | $1.73 Million | -$3.36 Million | 34.74x | N/A |
| 2019 | $69.88 Million | $964.05K | -$7.41 Million | 72.49x | N/A |
| 2020 | $39.74 Million | $929.12K | -$5.60 Million | 42.77x | N/A |
| 2021 | $76.82 Million | $780.64K | -$4.41 Million | 98.41x | N/A |
| 2022 | $66.23 Million | $1.14 Million | -$5.24 Million | 58.17x | N/A |
| 2023 | $37.09 Million | $1.07 Million | -$4.57 Million | 34.65x | N/A |
| 2024 | $45.03 Million | $1.03 Million | -$4.26 Million | 43.58x | N/A |
Competitor Companies of TLTFF by Market Capitalization
Companies near Theralase Technologies Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Theralase Technologies Inc. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Theralase Technologies Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, Theralase Technologies Inc.'s market cap moved from $82.12 Million to $ 37.09 Million, with a yearly change of -4.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $37.09 Million | -17.65% |
| 2024 | $45.03 Million | +21.43% |
| 2023 | $37.09 Million | -44.00% |
| 2022 | $66.23 Million | -13.79% |
| 2021 | $76.82 Million | +93.33% |
| 2020 | $39.74 Million | -43.14% |
| 2019 | $69.88 Million | +16.01% |
| 2018 | $60.24 Million | +17.34% |
| 2017 | $51.34 Million | +2.00% |
| 2016 | $50.33 Million | -38.71% |
| 2015 | $82.12 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Theralase Technologies Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.09 Million USD |
| MoneyControl | $37.09 Million USD |
| MarketWatch | $37.09 Million USD |
| marketcap.company | $37.09 Million USD |
| Reuters | $37.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.